CLNN | tickerfilter.com

Fundamental analysis

42%

Profitability 35%

Dept financing 43%

Liquidity 75%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

6.46%

1 Month

20.34%

3 Months

-8.62%

6 Months

-19.23%

1 Year

21.70%

2 Year

971.00%

Key data

Stock price

$5.36

P/E Ratio

0.00

DAY RANGE

$5.14 - $5.49

EPS

-$4.12

52 WEEK RANGE

$2.28 - $13.50

52 WEEK CHANGE

$21.70

MARKET CAP

60.193 M

YIELD

N/A

SHARES OUTSTANDING

10.334 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-07-2025

BETA

0.30

PUBLIC FLOAT

AVERAGE 10 VOLUME

$64,778

AVERAGE 30 VOLUME

$68,782

Company detail

CEO: Robert D. Etherington
Region: US
Website: clene.com
Employees: 100
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Clene Inc. focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis. The company also markets and distributes dietary supplements.

CLNN - Clene Inc.